{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:56:15Z","timestamp":1793145375441,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271557"],"award-info":[{"award-number":["82271557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060258"],"award-info":[{"award-number":["82060258"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460276"],"award-info":[{"award-number":["82460276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaad.2025.02.072","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:16:50Z","timestamp":1740741410000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database study"],"prefix":"10.1016","volume":"93","author":[{"given":"Wenjia","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengcheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaad.2025.02.072_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14740338.2022.2102605","article-title":"Oral isotretinoin for acne: a complete overview","volume":"21","author":"Villani","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.jaad.2025.02.072_bib2","doi-asserted-by":"crossref","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.072_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00403-020-02152-4","article-title":"Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions","volume":"313","author":"Chu","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2025.02.072_bib4","first-page":"23","article-title":"Isotretinoin and psychiatric adverse effects: a literature review","volume":"38","author":"Lotsaris","year":"2024","journal-title":"Rev Clin Pharmacol Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.072_bib5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/jdv.16489","article-title":"Suicidal risk with isotretinoin treatment - a never-ending story","volume":"34","author":"Gieler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2025.02.072_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14740338.2017.1344641","article-title":"Psychiatric disorders, acne and systemic retinoids: comparison of risks","volume":"16","author":"Le Moigne","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaad.2025.02.072_bib7","article-title":"Isotretinoin and neuropsychiatric side effects: continued vigilance is needed","volume":"6","author":"Bremner","year":"2021","journal-title":"J Affect Disord Rep"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.072_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.10r05993","article-title":"Retinoic acid and affective disorders: the evidence for an association","volume":"73","author":"Bremner","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.jaad.2025.02.072_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/ced\/llae287","article-title":"Evaluating the relationship between depression, suicidal thoughts, and ulcerative colitis in acne patients on isotretinoin: a case-control study","volume":"49","author":"Verma","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.072_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamadermatol.2023.4579","article-title":"Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis","volume":"160","author":"Tan","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.02.072_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jad.2021.09.055","article-title":"Risk of psychiatric disorders in patients taking isotretinoin: a nationwide, population-based, cohort study in Taiwan","volume":"296","author":"Chen","year":"2022","journal-title":"J Affect Disord"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.072_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamadermatol.2023.4577","article-title":"Isotretinoin and adverse psychiatric effects","volume":"160","author":"Magin","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.02.072_bib13","article-title":"The controversies surrounding acne and suicide: essential knowledge for clinicians","volume":"15","author":"Gupta","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.072_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/pde.15595","article-title":"The occurrence of mental health symptoms in isotretinoin-treated adolescents","volume":"41","author":"Miller","year":"2024","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.072_bib16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2025.02.072_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbi.2013.10.008","article-title":"Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS)","volume":"47","author":"Xu","year":"2014","journal-title":"J Biomed Inform"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.072_bib18","first-page":"314","article-title":"Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance","volume":"11","author":"Zink","year":"2013","journal-title":"Chin J Nat Med"},{"issue":"8","key":"10.1016\/j.jaad.2025.02.072_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071456","article-title":"Fluid retention-associated adverse events in patients treated with BCR:: ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jaad.2025.02.072_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.072_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.jaad.2025.02.072_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"10.1016\/j.jaad.2025.02.072_bib23","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2025.02.072_bib24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00403-024-03293-6","article-title":"Disproportionality analysis of psychiatric morbidities associated with isotretinoin using VigiBase","volume":"316","author":"Xia","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"10.1016\/j.jaad.2025.02.072_bib25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2019.1416","article-title":"Psychiatric adverse events in patients taking isotretinoin as reported in a food and drug administration database from 1997 to 2017","volume":"155","author":"Singer","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.02.072_bib26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamadermatol.2020.2330","article-title":"Quality of life assessed using Skindex-16 scores among patients with acne receiving isotretinoin treatment","volume":"156","author":"Secrest","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.072_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamadermatol.2017.5540","article-title":"The PHQ-2 in dermatology-standardized screening for depression and suicidal ideation","volume":"154","author":"McDonald","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.072_bib28","first-page":"214","article-title":"Isotretinoin induced psychotic mania: a case report","volume":"32","author":"Kurhan","year":"2021","journal-title":"T\u00fcrk Psikiyatri Derg"},{"key":"10.1016\/j.jaad.2025.02.072_bib29","article-title":"Isotretinoin-induced psychotic episode in a 17-year-old adolescent male","volume":"8","author":"Elhusein","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"Supplement_1","key":"10.1016\/j.jaad.2025.02.072_bib30","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1093\/schbul\/sbaa029.669","article-title":"T109. traversing the transdiagnostic gap between depression, mania and psychosis with natural language processing","volume":"46","author":"Patel","year":"2020","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.jaad.2025.02.072_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jad.2009.09.005","article-title":"Psychiatric reactions to isotretinoin in patients with bipolar disorder","volume":"122","author":"Schaffer","year":"2010","journal-title":"J Affect Disord"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.072_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5498\/wjp.v5.i2.222","article-title":"Inter-relationships between isotretinoin treatment and psychiatric disorders: depression, bipolar disorder, anxiety, psychosis and suicide risks","volume":"5","author":"Ludot","year":"2015","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.jaad.2025.02.072_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1744-859X-8-2","article-title":"Isotretinoin and psychopathology: a review","volume":"8","author":"Kontaxakis","year":"2009","journal-title":"Ann Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.jaad.2025.02.072_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/15622970903449853","article-title":"Genetic vulnerability and isotretinoin-induced psychiatric adverse events","volume":"11","author":"Kontaxakis","year":"2010","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.jaad.2025.02.072_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/09546634.2016.1230175","article-title":"The weeks and the cumulative doses of the first adverse events related to oral isotretinoin in acne patients: analysis of 300 patients","volume":"28","author":"Demirseren","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2025.02.072_bib36","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2133.2010.10152.x","article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:48:18Z","timestamp":1766112498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225003688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0190962225003688"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.072","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reported psychiatric adverse events among isotretinoin users: Monitoring priorities from a 20-year FDA Adverse Event Reporting System database study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}